Biote (BTMD) Common Equity (2020 - 2026)

Biote's Common Equity history runs 7 years deep, the most recent figure standing at -$48.0 million for Q1 2026.

• In Q1 2026, Common Equity rose 43.47% year-over-year to -$48.0 million; the TTM figure through Mar 2026 stood at -$48.0 million (up 43.47% YoY), while the FY2025 annual figure was -$58.5 million, up 42.72% from the prior year.
• Common Equity was -$48.0 million for Q1 2026 at Biote, up from -$58.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $10.7 million in Q1 2022 to a low of -$141.5 million in Q2 2024.
• Historically, Common Equity has averaged -$69.7 million across 5 years, with a median of -$70.8 million in 2022.
• Biggest YoY gain for Common Equity was 201.52% in 2022; the steepest drop was 5136.29% in 2022.
• A 5-year view of Common Equity shows it stood at -$58.3 million in 2022, then jumped by 37.29% to -$36.5 million in 2023, then slumped by 179.65% to -$102.2 million in 2024, then surged by 42.72% to -$58.5 million in 2025, then increased by 18.08% to -$48.0 million in 2026.
• The last three Common Equity figures came in at -$48.0 million (Q1 2026), -$58.5 million (Q4 2025), and -$65.5 million (Q3 2025), per Business Quant data.